Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignanciesFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies, Published online: 12 February 2018; doi:10.1038/s41408-018-0055-xFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Arnon P. Kater Sanne H. Tonino Marjolein Spiering Martine E D Chamuleau Roberto Liu Adeboye Henry Adewoye Jie Gao Lyndah Dreiling Yan Xin Jeanette K. Doorduijn Marie Jos é Kersten Source Type: research